SE0103509D0 - Rosuvastatin in pre demented states - Google Patents

Rosuvastatin in pre demented states

Info

Publication number
SE0103509D0
SE0103509D0 SE0103509A SE0103509A SE0103509D0 SE 0103509 D0 SE0103509 D0 SE 0103509D0 SE 0103509 A SE0103509 A SE 0103509A SE 0103509 A SE0103509 A SE 0103509A SE 0103509 D0 SE0103509 D0 SE 0103509D0
Authority
SE
Sweden
Prior art keywords
demented
rosuvastatin
states
dementia
rosuvastiatin
Prior art date
Application number
SE0103509A
Other languages
English (en)
Inventor
Hans Basun
Piser Timothy
Ihor Rak
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103509A priority Critical patent/SE0103509D0/sv
Publication of SE0103509D0 publication Critical patent/SE0103509D0/sv
Priority to ARP020103895A priority patent/AR036891A1/es
Priority to KR10-2004-7005585A priority patent/KR20040058201A/ko
Priority to BR0213434-9A priority patent/BR0213434A/pt
Priority to CA002463597A priority patent/CA2463597A1/en
Priority to EP02783893A priority patent/EP1446123A1/en
Priority to PL02369573A priority patent/PL369573A1/xx
Priority to JP2003535798A priority patent/JP2005505605A/ja
Priority to CNA028253477A priority patent/CN1604780A/zh
Priority to US10/492,971 priority patent/US20060229321A1/en
Priority to MXPA04003631A priority patent/MXPA04003631A/es
Priority to RU2004112422/14A priority patent/RU2004112422A/ru
Priority to IL16138002A priority patent/IL161380A0/xx
Priority to PCT/SE2002/001911 priority patent/WO2003032995A1/en
Priority to HU0401798A priority patent/HUP0401798A3/hu
Priority to IS7218A priority patent/IS7218A/is
Priority to ZA200402844A priority patent/ZA200402844B/en
Priority to CO04035705A priority patent/CO5580773A2/es
Priority to NO20041840A priority patent/NO20041840L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
SE0103509A 2001-10-19 2001-10-19 Rosuvastatin in pre demented states SE0103509D0 (sv)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SE0103509A SE0103509D0 (sv) 2001-10-19 2001-10-19 Rosuvastatin in pre demented states
ARP020103895A AR036891A1 (es) 2001-10-19 2002-10-17 Rosuvastatina en estados predemenciales
HU0401798A HUP0401798A3 (en) 2001-10-19 2002-10-18 Use of rosuvastatin for preparation of pharmaceutical compositions usable in pre demented states
CNA028253477A CN1604780A (zh) 2001-10-19 2002-10-18 在前痴呆状态中使用罗苏伐他汀
RU2004112422/14A RU2004112422A (ru) 2001-10-19 2002-10-18 Роувастатин в преддеменционных состояниях
CA002463597A CA2463597A1 (en) 2001-10-19 2002-10-18 Rosuvastatin in pre demented states
EP02783893A EP1446123A1 (en) 2001-10-19 2002-10-18 Rosuvastatin in pre demented states
PL02369573A PL369573A1 (en) 2001-10-19 2002-10-18 Rosuvastatin in pre demented states
JP2003535798A JP2005505605A (ja) 2001-10-19 2002-10-18 前痴呆状態におけるロスバスタチン
KR10-2004-7005585A KR20040058201A (ko) 2001-10-19 2002-10-18 치매전 상태에 사용되는 로수바스타틴
US10/492,971 US20060229321A1 (en) 2001-10-19 2002-10-18 Rosuvastatin in pre demented states
MXPA04003631A MXPA04003631A (es) 2001-10-19 2002-10-18 Rosuvastatina en estados de pre-demencia.
BR0213434-9A BR0213434A (pt) 2001-10-19 2002-10-18 Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitável
IL16138002A IL161380A0 (en) 2001-10-19 2002-10-18 Rosuvastatin in pre demented states
PCT/SE2002/001911 WO2003032995A1 (en) 2001-10-19 2002-10-18 Rosuvastatin in pre demented states
IS7218A IS7218A (is) 2001-10-19 2004-04-13 Notkun rósúvastatíns á forstigi vitglapa
ZA200402844A ZA200402844B (en) 2001-10-19 2004-04-15 Rosuvastatin in pre demented states.
CO04035705A CO5580773A2 (es) 2001-10-19 2004-04-19 Rosuvastatina en estados pre dementes
NO20041840A NO20041840L (no) 2001-10-19 2004-05-05 Rosuvastatin ved predemente tilstander

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103509A SE0103509D0 (sv) 2001-10-19 2001-10-19 Rosuvastatin in pre demented states

Publications (1)

Publication Number Publication Date
SE0103509D0 true SE0103509D0 (sv) 2001-10-19

Family

ID=20285721

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103509A SE0103509D0 (sv) 2001-10-19 2001-10-19 Rosuvastatin in pre demented states

Country Status (19)

Country Link
US (1) US20060229321A1 (sv)
EP (1) EP1446123A1 (sv)
JP (1) JP2005505605A (sv)
KR (1) KR20040058201A (sv)
CN (1) CN1604780A (sv)
AR (1) AR036891A1 (sv)
BR (1) BR0213434A (sv)
CA (1) CA2463597A1 (sv)
CO (1) CO5580773A2 (sv)
HU (1) HUP0401798A3 (sv)
IL (1) IL161380A0 (sv)
IS (1) IS7218A (sv)
MX (1) MXPA04003631A (sv)
NO (1) NO20041840L (sv)
PL (1) PL369573A1 (sv)
RU (1) RU2004112422A (sv)
SE (1) SE0103509D0 (sv)
WO (1) WO2003032995A1 (sv)
ZA (1) ZA200402844B (sv)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2537271A1 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005051921A1 (en) 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
DE602004032465D1 (de) 2003-12-02 2011-06-09 Teva Pharma Referenzstandard zur charakterisierung von rosuvastatin
CA2573857A1 (en) 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
US7612203B2 (en) 2005-02-22 2009-11-03 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
WO2007022488A2 (en) 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
US20030100493A1 (en) * 2001-07-19 2003-05-29 Sol Weiss Sublingual use of inhibitors in the biosynthesis of cholesterol

Also Published As

Publication number Publication date
KR20040058201A (ko) 2004-07-03
RU2004112422A (ru) 2005-04-10
ZA200402844B (en) 2005-01-24
HUP0401798A3 (en) 2005-06-28
WO2003032995A1 (en) 2003-04-24
HUP0401798A2 (hu) 2005-01-28
US20060229321A1 (en) 2006-10-12
MXPA04003631A (es) 2004-07-30
JP2005505605A (ja) 2005-02-24
BR0213434A (pt) 2004-11-09
EP1446123A1 (en) 2004-08-18
CO5580773A2 (es) 2005-11-30
IL161380A0 (en) 2004-09-27
PL369573A1 (en) 2005-05-02
WO2003032995A8 (en) 2004-06-03
CA2463597A1 (en) 2003-04-24
IS7218A (is) 2004-04-13
CN1604780A (zh) 2005-04-06
NO20041840L (no) 2004-05-05
AR036891A1 (es) 2004-10-13

Similar Documents

Publication Publication Date Title
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
ATE346039T1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
RU2005108133A (ru) Дипептиднитрильные ингибиторы катепсина к
DE60331187D1 (de) Kinaseinhibitoren
ATE344253T1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
NO20051892L (no) Ny forbindelse
NO20051893L (no) Ny forbindelse
TNSN06138A1 (fr) Inhibitors of the mutant form of kit
DE60127537D1 (de) VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE
DE60139466D1 (de) Behandlung von diabetes
DE50201780D1 (de) Halogensubstituierte aminodicarbonsäurederivate als arzneimittel zur behandlung von herz-kreislauf-erkrankungen
GB0130677D0 (en) Medicaments and novel compounds
SE0103509D0 (sv) Rosuvastatin in pre demented states
DK1030667T3 (da) Anvendelse af mirtazapin til fremstilling af et lægemiddel til behandling af sövnapnö
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
DK0583271T3 (da) Arylmorpholin, fremstilling og anvendelse
DE60200160D1 (de) Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
JP2005505605A5 (sv)
SE0004827D0 (sv) Therapeutic compounds
DE60313208D1 (de) Phenyl-piperidin-4-yliden-methyl-benzamidderivate zur behandlung von schmerz oder magen-darm-erkrankungen
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs